PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Short Interest Up 152.9% in September

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 17,200 shares, a growth of 152.9% from the August 31st total of 6,800 shares. Based on an average daily trading volume, of 16,800 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.2% of the shares of the stock are sold short.

PharmaCyte Biotech Stock Up 2.2 %

Shares of PharmaCyte Biotech stock traded up $0.04 on Friday, reaching $1.84. The company’s stock had a trading volume of 18,277 shares, compared to its average volume of 21,616. The stock has a 50-day moving average price of $1.80 and a 200-day moving average price of $2.03. The company has a market capitalization of $15.55 million, a P/E ratio of -1.53 and a beta of -0.22. PharmaCyte Biotech has a 52-week low of $1.39 and a 52-week high of $2.58.

PharmaCyte Biotech (NASDAQ:PMCB) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.85) earnings per share for the quarter.

Hedge Funds Weigh In On PharmaCyte Biotech

An institutional investor recently raised its position in PharmaCyte Biotech stock. K2 Principal Fund L.P. lifted its position in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) by 17.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 304,613 shares of the company’s stock after buying an additional 46,132 shares during the quarter. K2 Principal Fund L.P. owned approximately 3.53% of PharmaCyte Biotech worth $655,000 at the end of the most recent reporting period. Institutional investors own 34.24% of the company’s stock.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.